Recent Updates
Recently added Catalysts

Prevention of Acute Rejection in Renal Transplant: one US-listed biotech with a clinical-stage programme

Immunology & InflammationUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$226Muniverse median $1.20B
Allocated capital$226M$226M competing
Phase 3 or filed00 mid, 1 early
Pure plays1this indication only
Capital rank250/299crowding rank 253

Prevention of Acute Rejection in Renal Transplant is uncontested. Eledon Pharmaceuticals (ELDN) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with AT-1501 in phase 1.

There is no public comparable to price it against, and ELDN runs clinical programmes in this indication and nothing else, so its $226M market cap is a direct read on what the market thinks this programme is worth.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$226M of allocated capital sits in Prevention of Acute Rejection in Renal Transplant, ranking it 250th of 299 indications by the money committed to it.

Companies developing drugs for Prevention of Acute Rejection in Renal Transplant 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ELDNEledon PharmaceuticalsAT-1501Phase 11$226MYes1 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Prevention of Acute Rejection in Renal Transplant counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Prevention of Acute Rejection in Renal Transplant has one competitor and a median of $226M.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery1 company · $265M · median $1.1BUncontestedIdiopathic Membranous Nephropathy1 company · $279M · median $838MUncontestedCOPD1 company · $167M · median $333MUncontestedPemphigus1 company · $148M · median $590MUncontestedAcute Respiratory Distress Syndrome1 company · $136M · median $272MUncontestedChildhood-onset Systemic Lupus Erythematosus1 company · $69M · median $276MUncontestedCOPD Exacerbation1 company · $61M · median $122MUncontestedDiffuse Cutaneous Systemic Sclerosis1 company · $51M · median $101MUncontested

Prevention of Acute Rejection in Renal Transplant pipeline questions

Which biotech companies are developing drugs for Prevention of Acute Rejection in Renal Transplant?

Eledon Pharmaceuticals (ELDN, AT-1501, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Prevention of Acute Rejection in Renal Transplant.

How advanced is the Prevention of Acute Rejection in Renal Transplant pipeline?

Of the 1 clinical-stage programme in Prevention of Acute Rejection in Renal Transplant, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Prevention of Acute Rejection in Renal Transplant?

No. ELDN is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Prevention of Acute Rejection in Renal Transplant, which is why the indication is classified as uncontested.

When is the next Prevention of Acute Rejection in Renal Transplant catalyst?

The next dated catalyst in Prevention of Acute Rejection in Renal Transplant is ELDN on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map